My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 8 485 / DOI: 10.3332/ecancer.2014.485

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Keywords: Drug repurposing, cimetidine, immunostimulant, ReDO project

Loading Article Metrics ... Please wait

Related articles

Special Issue: The past and future of breast cancer treatment—from the papyrus to individualised treatment approaches

Abstract | Full Article | PDF Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.746

Special Issue: Radioguided localisation of non-palpable lesions of the breast in Costa Rica: Review of results of our first 800 patients in private practice

Abstract | Full Article | PDF | Spanish Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.745

Special Issue: The Veronesi quadrantectomy: an historical overview

Abstract | Full Article | PDF Published: 08 Jun 2017 / DOI: 10.3332/ecancer.2017.743

Case Report: Volumetric arc therapy for total scalp irradiation: case report for a recurrent basal cell carcinoma of the scalp

Abstract | Full Article | PDF Published: 11 May 2017 / DOI: 10.3332/ecancer.2017.737

Review: Tobacco in post-conflict settings: the case of Iraq

Abstract | Full Article | PDF Published: 28 Apr 2017 / DOI: 10.3332/ecancer.2017.735



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence